Clarivate's annual Drugs to Watch report, released today from London, identifies eleven innovative therapies with blockbuster potential in metabolic disease, oncology, immunology, and more, leveraging AI-powered intelligence for pharmaceutical R&D strategy.

HUTCHMED has initiated the Phase III part of its trial evaluating surufatinib combined with camrelizumab, nab-paclitaxel, and gemcitabine as first-line therapy for metastatic pancreatic ductal adenocarcinoma in China.

Vietnam's pharmaceutical exports reached $312 million last year, ranking fourth in Southeast Asia, driven by improved production capacities, GMP-compliant factories, and ongoing regulatory digital transformation.

The European Parliament’s Public Health Committee has adopted a draft bill to enhance investment and manufacturing capacity for critical medicines, aiming to reduce EU dependency on external suppliers.

The European Parliament's Public Health Committee has adopted a draft bill to boost investment in critical medicines manufacturing and diversify supply chains across the EU.

The EMA Management Board celebrated the political agreement on groundbreaking EU pharmaceutical legislation and outlined 2026 priorities focused on implementation, innovation, and regulatory modernization.[1]

Dr. Lu Xianping, founder and chairman of Chipscreen Biosciences, has been named the Chinese mainland winner of the EY Entrepreneur Of The Year 2025 awards for his contributions to China's pharmaceutical innovation ecosystem.

Theriva Biologics announces positive EMA scientific advice on the Phase 3 trial design of VCN-01 combined with standard chemotherapy for first-line metastatic pancreatic ductal adenocarcinoma treatment.[5]

Ipsen has signed a deal worth up to $1 billion with China's Simcere to acquire rights to a preclinical antibody-drug conjugate (ADC), enhancing its oncology pipeline with manufacturing and regulatory responsibilities.

Swedish biotech Diamyd Medical aligns with FDA to advance primary efficacy readout in its registrational Phase 3 trial for antigen-specific immunotherapy Diamyd, targeting recent-onset type 1 diabetes patients.